BioCentury
ARTICLE | Financial News

ViaCyte attracts crossover investors for $80M series D

November 29, 2018 5:02 AM UTC

ViaCyte Inc. (San Diego, Calif.) announced an $80 million tranched series D round to fund development of its Type I diabetes stem cell therapies.

ViaCyte President and CEO Paul Laikind declined to disclose the triggers for the financing's two tranches but said they are progress based...